National Health Investors (NHI) Tops Q4 EPS by 1c, Introduces FY 2026 guidance
National Health Investors (NYSE: NHI) reported Q4 EPS of $0.80, $0.01 better than the analyst estimate of $0.79. Revenue for the quarter came in at $105.8 million versus the consensus estimate of $73.55 million.
NHI is introducing its 2026 annual guidance range which includes the following:
NAREIT FFO per diluted share range of $4.94 - $4.99;
Normalized FFO per diluted share range of $4.94 - $4.99; and
Normalized FAD range of $248.9 million - $251.4 million
For earnings history and earnings-related data on National Health Investors (NHI) click here.
